SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody

Infectious Disease, COVID-19

Anti-SARS-CoV-2 (COVID-19) NSP14 (ExoN) antibody (9187) was raised against a peptide corresponding to 14 amino acids near the center of SARS-CoV-2 (COVID-19) NSP14 (ExoN) protein.

The immunogen is located between 30-80 amino acids of SARS-CoV-2 (COVID-19) NSP14 (ExoN).

SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody is affinity chromatography purified via peptide column.

IgG

SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 (COVID-19) NSP14 (ExoN) antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

YP_009725309.1

43740578

ORF1ab

Severe acute respiratory syndrome coronavirus 2

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP14 (ExoN) is an enzyme possessing two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity (3, 4, 5). It acts as a proofreading exoribonuclease for RNA replication, thereby lowering The sensitivity of the virus to RNA mutagens(6, 7, 8).

Hui et al. Int J Infect Dis. 2020; 91:264-266.

Bouvet et. al. PLoS Pathog. 2010; 6:E1000863-E1000863

Denison et. al. RNA Biol. 2011; 8:270-279

Agostini et. al. MBio 2018; 9:0-0